Literature DB >> 22885698

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Marcus Dühren-von Minden1, Rudolf Übelhart, Dunja Schneider, Thomas Wossning, Martina P Bach, Maike Buchner, Daniel Hofmann, Elena Surova, Marie Follo, Fabian Köhler, Hedda Wardemann, Katja Zirlik, Hendrik Veelken, Hassan Jumaa.   

Abstract

B-cell antigen receptor (BCR) expression is an important feature of chronic lymphocytic leukaemia (CLL), one of the most prevalent B-cell neoplasias in Western countries. The presence of stereotyped and quasi-identical BCRs in different CLL patients suggests that recognition of specific antigens might drive CLL pathogenesis. Here we show that, in contrast to other B-cell neoplasias, CLL-derived BCRs induce antigen-independent cell-autonomous signalling, which is dependent on the heavy-chain complementarity-determining region (HCDR3) and an internal epitope of the BCR. Indeed, transferring the HCDR3 of a CLL-derived BCR provides autonomous signalling capacity to a non-autonomously active BCR, whereas mutations in the internal epitope abolish this capacity. Because BCR expression was required for the binding of secreted CLL-derived BCRs to target cells, and mutations in the internal epitope reduced this binding, our results indicate a new model for CLL pathogenesis, with cell-autonomous antigen-independent signalling as a crucial pathogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885698     DOI: 10.1038/nature11309

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells.

Authors:  Fabian Köhler; Eva Hug; Cathrin Eschbach; Sonja Meixlsperger; Elias Hobeika; Juliane Kofer; Hedda Wardemann; Hassan Jumaa
Journal:  Immunity       Date:  2008-12-11       Impact factor: 31.745

3.  B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Sergey Krysov; Andrew J Davies; Andrew J Steele; Graham Packham
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

4.  N-linked glycosylation selectively regulates autonomous precursor BCR function.

Authors:  Rudolf Ubelhart; Martina P Bach; Cathrin Eschbach; Thomas Wossning; Michael Reth; Hassan Jumaa
Journal:  Nat Immunol       Date:  2010-07-11       Impact factor: 25.606

5.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Authors:  Roberta Bichi; Susan A Shinton; Eric S Martin; Anatoliy Koval; George A Calin; Rossano Cesari; Giandomenico Russo; Richard R Hardy; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 7.  Autoinhibition and adapter function of Syk.

Authors:  Yogesh Kulathu; Gesina Grothe; Michael Reth
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

8.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

9.  Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.

Authors:  George F Widhopf; Laura Z Rassenti; Traci L Toy; John G Gribben; William G Wierda; Thomas J Kipps
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

10.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.

Authors:  Z M Sthoeger; M Wakai; D B Tse; V P Vinciguerra; S L Allen; D R Budman; S M Lichtman; P Schulman; L R Weiselberg; N Chiorazzi
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  199 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

2.  Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.

Authors:  Anna Parente-Ribes; Sigrid S Skånland; Simone Bürgler; Audun Os; Dong Wang; Bjarne Bogen; Geir E Tjønnfjord; Kjetil Taskén; Ludvig A Munthe
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 3.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

4.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 5.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

6.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

7.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

Review 10.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.